[Federal Register Volume 75, Number 163 (Tuesday, August 24, 2010)]
[Notices]
[Pages 51984-51985]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-21014]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Federal Advisory Committee; Meeting of the Uniform Formulary 
Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and 
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) 
the Department of Defense announces that the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel) will 
meet September 23, 2010, in Washington, DC.

DATES: The meeting will be held on September 23, 2010, from 9 a.m.-12 
p.m.
    A closed Administrative Work Meeting will be held from 8 a.m. to 9 
a.m.

ADDRESSES: The meetings will be held at the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Stacia Spridgen, 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel; 2450 Stanley Road, Suite 208; Ft. Sam Houston, TX 78234-6102; 
Telephone: (210) 295-1271, Fax: (210) 295-2789, E-mail: 
<a href="/cdn-cgi/l/email-protection#e0a281909285919585939493a0948d81ce8f9384ce8d898c"><span class="__cf_email__" data-cfemail="53113223213622263620272013273e327d3c20377d3e3a3f">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:

Purpose of Meeting

    The Panel will review and comment on recommendations made to the 
Director, TRICARE Management Activity, by the Pharmacy and Therapeutics 
Committee regarding the Uniform Formulary.

Meeting Agenda

    Sign-In; Welcome and Opening Remarks; Public Citizen Comments; 
Scheduled Therapeutic Class Reviews--Ophthalmic Agents (Nonsteroidal 
Anti-Inflammatory, Mast Cell Stabilizers, Steroids, and 
Antihistamines), Renin-Angiotensin Antihypertensives (RAAS), pertinent 
utilization management issues, drugs recommended for non-formulary 
placement due to non-compliance with the National Defense Authorization 
Act for Fiscal Year 2008, Section 703; Panel Discussions and Vote; and 
comments following each therapeutic class review.

Meeting Accessibility

    Pursuant to 5 U.S.C. 552b, as amended, and Title 41, Code of 
Federal Regulations (CFR), Section 102-3.140 through 102-3.165, and the 
availability of space this meeting is open to the public. Seating is 
limited and will be provided only to the first 220 people signing in. 
All persons must sign in legibly.

Administrative Work Meeting

    Prior to the public meeting the Panel will conduct an 
Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss 
administrative matters of the Panel. The Administrative Work Meeting 
will be held at the Naval Heritage Center, 701 Pennsylvania Avenue, 
NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.

Written Statements

    Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (DFO). The DFO's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than 5 business days prior 
to the meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.

Public Comments

    In addition to written statements, the Panel will set aside 1 hour 
for individuals or interested groups to address the Panel. To ensure 
consideration of their comments, individuals and interested groups 
should submit written statements as outlined in this notice; but if 
they still want to address the Panel, then they will be afforded the 
opportunity to register to address the Panel. The Panel's DFO will have 
a ``Sign-Up Roster'' available at the Panel meeting, for registration 
on a first-come, first-served basis. Those wishing to address the Panel 
will be given no more than 5 minutes to present their comments, and at 
the end of the 1 hour time period no further public comments will be 
accepted. Anyone who signs up to address the Panel, but is unable to do 
so due to the time limitation, may submit their comments in writing; 
however, they must understand that their written comments may not be 
reviewed prior to the Panel's deliberation. Accordingly,

[[Page 51985]]

the Panel recommends that individuals and interested groups consider 
submitting written statements instead of addressing the Panel.

    Dated: August 19, 2010.
Mitchell S. Bryman,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2010-21014 Filed 8-23-10; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>